Use of PQQ in preparation of modulator for menstrual cycle disorders

By using pyrroliquinoline quinone and its derivatives as menstrual cycle disorder regulators, the side effects and drug resistance of hormone therapy in the prior art were solved, and effective prevention and treatment of menstrual cycle disorders were achieved, and significant treatment was shown Effect.

WO2024245461A1PCT designated stage expired Publication Date: 2024-12-05GUANGZHOU HUTONGYOUWU BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/106625
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-24
Filing Date
2024-07-22
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The prior art has failed to effectively solve the problem of menstrual cycle disorders, hormone therapy has side effects and drug resistance, and there is a lack of effective treatment plans.

Method used

Pyrroliquinoline quinone (PQQ) and its derivatives are used as regulators of menstrual cycle disorders, and the prevention of 5 to 60 mg/d or the therapeutic dosage of 10 to 800 mg/d is provided by oral means for prevention, improvement or treatment of menstrual periods. Symptoms of early, delayed, prolonged and irregular menstruation.

Benefits of technology

Preliminary experimental data show that oral PQQ has significant effects on preventing and treating menstrual cycle disorders, and has significant advantages over placebo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024106625-APPB-I100001
    Figure PCTCN2024106625-APPB-I100001
  • Figure PCTCN2024106625-APPB-I100002
    Figure PCTCN2024106625-APPB-I100002
Patent Text Reader

Abstract

Disclosed in the present invention is the use of PQQ in the preparation of a modulator for menstrual cycle disorders. Preliminary experimental data shows that oral PQQ has a significant effect of preventing, ameliorating or treating menstrual cycle disorders compared with a placebo.
Need to check novelty before this filing date? Find Prior Art

Description

Application of PQQ in the preparation of menstrual cycle disorder regulator Technical Field

[0001] The present invention relates to a new application of a compound, and in particular to an application of PQQ in the preparation of a menstrual cycle disorder regulator. Background Art

[0002] A normal menstrual cycle for women is 21 to 35 days, with an average of 28 days. The menstrual period typically lasts 2 to 8 days, with an average of 4 to 6 days. Menstrual volume is the total amount of blood lost during a menstrual period. Normal menstrual volume is 20 to 60 ml, while excess of 80 ml is considered menorrhagia.

[0003] Symptoms of menstrual disorders mainly include:

[0004] 1. Early menstruation: Early menstruation refers to a shortened menstrual cycle, shorter than 21 days, and occurs for more than two consecutive cycles. It is a biphasic basal body temperature of ovulatory functional uterine bleeding, a short follicular phase of only 7 or 8 days; or a luteal phase of less than 10 days, or a body temperature rise of less than 0.5°C.

[0005] 2. Delayed menstruation: Menstruation is missed for more than 7 days, or even every 40-50 days, and symptoms occur for more than 2 menstrual cycles. In women who ovulate, the basal body temperature is biphasic, but the follicular phase is long and the high temperature phase is low; in women who do not ovulate, the basal body temperature is monophasic.

[0006] 3. Prolonged Menstruation: Symptoms of this type of menstrual irregularity include a normal menstrual cycle but prolonged periods, lasting more than seven days or even two weeks. Those with inflammation often experience lower abdominal pain, worsening menstrual pain, and heavy vaginal discharge that is yellow or yellowish-white, thick, and has a strong odor. Those with incomplete corpus luteum atrophy also experience heavy menstruation. Those with prolonged endometrial repair may experience a small amount of persistent vaginal bleeding after their normal menstrual period.

[0007] 4. Irregular menstruation: menstruation is early or late, and the cycle is shorter than 21 days or longer than 35 days.

[0008] Menstrual cycle disorders are a common disease among women. If they continue for a long time, mild cases will accelerate facial aging, and severe cases will lead to serious gynecological diseases, causing inconvenience to women's normal life and affecting their health.

[0009] Conventional treatments for menstrual irregularities primarily rely on hormones. However, these treatments have significant side effects, are prone to drug resistance, and are prone to relapse, resulting in only a small number of women with severe menstrual irregularities adopting this approach. However, there are also reports of Traditional Chinese Medicine (TCM) treating menstrual irregularities, demonstrating some efficacy.

[0010] Pyrroloquinoline quinone (PQQ) is a tricarboxylic acid quinone compound with the CAS No. 72909-34-3 and the IUPAC designation 4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid. PQQ is widely found in various food ingredients, with concentrations ranging from 3.65 to 61 ng / g. PQQ concentrations in vegetables like parsley and green peppers, fruits like kiwi and papaya, green tea and oolong tea, and commonly consumed tofu are all around 30 ng / g. Studies have shown that PQQ can stimulate the rapid growth of microbial, plant, animal, and human cells; scavenge excess free radicals in the body, protecting the body from oxidative damage; and accelerate the oxidation of acetaldehyde to acetic acid, thereby reducing acetaldehyde levels in the body and potentially mitigating the toxic effects of alcohol on the liver. CN110870866A discloses the use of pyrroloquinoline quinone in the preparation of drugs for preventing and treating acute altitude sickness and acute altitude hypoxia injury; CN110151764A discloses that pyrroloquinoline quinone can reduce lipopolysaccharide-induced inflammatory responses in animal fibroblasts and intestines; CN106265730A discloses the use of pyrroloquinoline quinone (PQQ) in reversing multidrug resistance of tumors; CN105963297A discloses the use of pyrroloquinoline quinone in adjuvant therapy after chemotherapy; CN103191115A discloses the use of pyrroloquinoline quinone in the treatment and / or improvement of diabetic foot. Technical issues

[0011] No studies have shown that PQQ can be used to treat menstrual cycle disorders. Solution

[0012] The purpose of the present invention is to overcome at least one deficiency of the prior art and provide a use of PQQ in the preparation of a menstrual cycle disorder regulator.

[0013] The technical solution adopted by the present invention is:

[0014] The first aspect of the present invention provides:

[0015] Application of pyrroloquinoline quinone and its derivatives in the preparation of menstrual cycle disorder regulators.

[0016] In some instances, the menstrual cycle disorder has one of the following symptoms:

[0017] Early menstruation;

[0018] Delayed menstruation;

[0019] Prolonged menstrual period;

[0020] Menstruation is irregular.

[0021] In some examples, the menstrual cycle disorder does not include menstrual cycle disorder caused by endometriosis.

[0022] In some embodiments, the derivative of pyrroloquinoline quinone is a derivative that can be digested or metabolized in the body to yield pyrroloquinoline quinone.

[0023] In some embodiments, the derivative of pyrroloquinoline quinone is a derivative that can be hydrolyzed in the digestive tract to yield pyrroloquinoline quinone.

[0024] In some examples, the derivative of pyrroloquinoline quinone is a pharmaceutically or food-acceptable salt, C2-C6 ester, amide, hydrate, crystal, co-crystal or solvate thereof.

[0025] In some embodiments, the derivative of pyrroloquinoline quinone is the disodium salt of pyrroloquinoline quinone. The disodium salt of pyrroloquinoline quinone has better solubility and is more easily absorbed.

[0026] In some embodiments, the oral dosage is calculated as pyrroloquinoline quinone:

[0027] The dosage for preventing menstrual cycle disorders is 5 to 60 mg / d;

[0028] The dosage for improving or treating menstrual cycle disorders is 10-800 mg / d.

[0029] In some examples, the modulator is a functional food or a drug.

[0030] In some examples, the regulator further comprises acceptable excipients, including but not limited to excipients, flavoring agents, colorants, and antioxidants.

[0031] The second aspect of the present invention provides:

[0032] A method for preventing, improving or treating menstrual cycle disorders comprises the following steps: orally administering a preventive, improving or therapeutic amount of pyrroloquinoline quinone or at least one of its derivatives to a patient with menstrual cycle disorders.

[0033] In some instances, the menstrual cycle disorder has one of the following symptoms:

[0034] Early menstruation;

[0035] Delayed menstruation;

[0036] Prolonged menstrual period;

[0037] Menstruation is irregular.

[0038] In some examples, the menstrual cycle disorder does not include menstrual cycle disorder caused by endometriosis.

[0039] In some embodiments, the derivative of pyrroloquinoline quinone is a derivative that can be digested or metabolized in the body to yield pyrroloquinoline quinone.

[0040] In some embodiments, the derivative of pyrroloquinoline quinone is a derivative that can be hydrolyzed in the digestive tract to yield pyrroloquinoline quinone.

[0041] In some examples, the derivative of pyrroloquinoline quinone is a pharmaceutically or food-acceptable salt, C2-C6 ester, amide, hydrate, crystal, co-crystal or solvate thereof.

[0042] In some examples, the derivative of pyrroloquinoline quinone is the disodium salt of pyrroloquinoline quinone.

[0043] In some embodiments, the oral dosage is calculated as pyrroloquinoline quinone:

[0044] The dosage for preventing menstrual cycle disorders is 5 to 60 mg / d;

[0045] The dosage for improving or treating menstrual cycle disorders is 10-800 mg / d. Beneficial effects

[0046] Preliminary experimental data show that oral PQQ has a significant effect on preventing, alleviating or treating menstrual cycle disorders compared with placebo. DETAILED DESCRIPTION

[0047] In the present invention, pharmaceutically or food-acceptable derivatives of a compound particularly refer to simple derivatives thereof, particularly any of its lower esters, lower ethers, lower alkyl substituents, pharmaceutically acceptable salts, and lower amides, i.e., derivatives obtained by condensing a carboxylic acid, alcohol, or amine having 1 to 6, preferably 2 to 6, or 2 to 4, carbon atoms with the parent compound. In particular, the pyrroloquinoline quinone derivative has the following general formula:

[0048]

[0049] In the formula, R1 to R3 are the same or different and are selected from pharmaceutically acceptable groups such as H, C1 to C6 hydrocarbon groups, natural amino acid residues, Na, K, and Li.

[0050] Pharmaceutically acceptable salts of the compounds can be synthesized from the parent compounds by conventional chemical methods, such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Generally, these salts can be prepared by reacting the free base of the compound with an acid in water or an organic solvent, or a mixture of the two; typically, a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is used.

[0051] Acid addition salts can be prepared with various acids (inorganic and organic). Examples of acid addition salts include salts prepared with an acid selected from acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (such as L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (such as D-glucuronic acid), glutamic acid (such as L-glutamic acid), α-ketoglutaric acid, acetic acid. The group consisting of alkyd acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and valeric acid, as well as acylated amino acids and cation exchange resins.

[0052] The technical solution of the present invention is further illustrated below in conjunction with experiments.

[0053] The criteria for menstrual cycle disorders are as follows:

[0054] 1. Early menstruation: Early menstruation refers to a shortened menstrual cycle, shorter than 21 days, and occurs for more than two consecutive cycles. It is a biphasic basal body temperature of ovulatory functional uterine bleeding, a short follicular phase of only 7 or 8 days; or a luteal phase of less than 10 days, or a body temperature rise of less than 0.5°C.

[0055] 2. Delayed menstruation: Menstruation is missed for more than 7 days, or even every 40-50 days, and symptoms occur for more than 2 menstrual cycles. In women who ovulate, the basal body temperature is biphasic, but the follicular phase is long and the high temperature phase is low; in women who do not ovulate, the basal body temperature is monophasic.

[0056] 3. Prolonged Menstruation: Symptoms of this type of menstrual irregularity include a normal menstrual cycle but prolonged periods, lasting more than seven days or even two weeks. Those with inflammation often experience lower abdominal pain, worsening menstrual pain, and heavy vaginal discharge that is yellow or yellowish-white, thick, and has a strong odor. Those with incomplete corpus luteum atrophy also experience heavy menstruation. Those with prolonged endometrial repair may experience a small amount of persistent vaginal bleeding after their normal menstrual period.

[0057] 4. Irregular menstruation: menstruation is early or late, and the cycle is shorter than 21 days or longer than 35 days. PQQ for preventing menstrual cycle disorders

[0058] Eligible participants were those aged 16 to 30 years who had experienced one menstrual irregularity within six menstrual cycles. The preventive treatment was a tablet containing 8 mg of PQQ taken orally once daily. The study lasted six months. A control group received a tablet containing an equivalent amount of vitamin C once daily. PQQ is used to improve or treat menstrual cycle disorders

[0059] Eligibility criteria included patients aged 18 to 40 years who had experienced at least three menstrual irregularities within six menstrual cycles. Patients were administered a 50 mg PQQ tablet orally once daily for six months. The control group received an equivalent amount of vitamin C tablets orally once daily.

[0060] The experimental results are shown in Table 1.

[0061] Table 1

[0062]

[0063] The above is a further detailed description of the present invention and should not be considered as a limitation on the specific implementation of the present invention. For those skilled in the art, simple deductions or substitutions that do not depart from the concept of the present invention are within the scope of protection of the present invention.

Claims

1. Application of pyrroloquinoline quinone and its derivatives in the preparation of menstrual cycle disorder regulators.

2. The use according to claim 1, characterized in that: The menstrual cycle disorder has one of the following symptoms: Early menstruation; Delayed menstruation; Prolonged menstrual period; Menstruation is irregular.

3. The use according to claim 1, characterized in that: The derivatives of pyrroloquinoline quinone are derivatives that can be digested or metabolized in vivo to give pyrroloquinoline quinone.

4. The use according to claim 3, characterized in that: The derivatives of pyrroloquinoline quinone are derivatives which can be hydrolyzed in the digestive tract to obtain pyrroloquinoline quinone.

5. The use according to claim 3, characterized in that: The derivative of pyrroloquinoline quinone is a pharmaceutically or food-acceptable salt, C2-C6 ester, amide, hydrate, crystal, co-crystal or solvate thereof.

6. The use according to claim 1, characterized in that: Calculated in terms of pyrroloquinoline quinone, the oral dosage is: The dosage for preventing menstrual cycle disorders is 5 to 60 mg / d; The dosage for improving or treating menstrual cycle disorders is 10-800 mg / d.

7. The use according to claim 1, characterized in that: The regulator is a functional food or a medicine.

8. The use according to claim 1, characterized in that: The menstrual cycle disorder does not include menstrual cycle disorder caused by endometriosis.

9. A method for preventing, improving or treating menstrual cycle disorders, comprising the following steps: orally administering a preventive, improving or therapeutic amount of pyrroloquinoline quinone or at least one of its derivatives to a patient with menstrual cycle disorders.

10. The method according to claim 9, characterized in that Calculated in terms of pyrroloquinoline quinone, the oral dosage is: The dosage for preventing menstrual cycle disorders is 5 to 60 mg / d; The dosage for improving or treating menstrual cycle disorders is 10-800 mg / d.

11. The method according to claim 9, characterized in that The menstrual cycle disorder has one of the following symptoms: Early menstrual period; Delayed menstruation; Prolonged menstrual period; Menstruation is irregular.

12. The method according to claim 9, characterized in that The menstrual cycle disorder does not include menstrual cycle disorder caused by endometriosis.

13. The method according to claim 9, characterized in that The derivatives of pyrroloquinoline quinone are derivatives that can be digested or metabolized in vivo to give pyrroloquinoline quinone.

14. The method according to claim 13, characterized in that The derivatives of pyrroloquinoline quinone are derivatives which can be hydrolyzed in the digestive tract to obtain pyrroloquinoline quinone.

15. The method according to claim 13, characterized in that The derivative of pyrroloquinoline quinone is a pharmaceutically or food-acceptable salt, C2-C6 ester, amide, hydrate, crystal, co-crystal or solvate thereof.

Citation Information

Patent Citations

  • Pyrroloquinoline quinine, novel medicine applications of derivative and / or salt of pyrroloquinoline quinine and medicine composition

    CN104856996A

  • Application of pyrroloquinoline quinine to improvement on internal environment of female reproductive system

    CN105853502A

  • New use of PQQ and derivative thereof

    WO2022166599A1